RGD Modified Protein-Polymer Conjugates for pH-Triggered Targeted Thrombolysis

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Thrombosis Research

Background:

• Developing effective thrombolytic agent delivery systems is crucial for improving treatment outcomes.
• Current systems face challenges including short circulation times, systemic side effects, and lack of targeted activity.
• Targeted delivery and controlled release are key to enhancing thrombolytic efficacy and safety.

Purpose of the Study:

• To synthesize and evaluate a pH-triggered, RGD-peptide modified delivery system for urokinase-type plasminogen activator (uPA).
• To achieve prolonged circulation, targeted thrombus accumulation, and localized thrombolytic activity.
• To reduce the risk of adverse effects, particularly acute hemorrhage.

Main Methods:

• Conjugation of fluorescein isothiocyanate-labeled urokinase-type plasminogen activator (uPA) to oxidized dextran (Oxd) via a pH-sensitive imine linkage.
• Modification of the uPA-Oxd conjugate with RGD peptide for targeted binding.
• Assessment of conjugate stability, pH-triggered uPA release, and thrombolysis efficacy in vitro and potentially in vivo.

Main Results:

• The synthesized uPA-Oxd conjugates demonstrated enhanced stability against enzymatic hydrolysis compared to native uPA.
• uPA bioactivity was masked at physiological pH and restored under weakly acidic conditions, facilitating controlled release.
• RGD modification enabled specific targeting to thrombus sites via GP IIb/IIIa binding, enhancing thrombolysis and reducing hemorrhage risk.

Conclusions:

• The RGD-modified, pH-sensitive uPA-Oxd conjugates represent a promising platform for targeted local thrombolysis.
• This system offers potential for improved therapeutic outcomes in treating thrombotic conditions.
• The localized and triggered drug release mechanism minimizes systemic exposure and associated complications.